Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin

The European Investigators Network for Nebulized Antibiotics in Ventilator-associated Pneumonia

Research output: Contribution to journalArticlepeer-review

19 Downloads (Pure)

Abstract

The use of nebulized antibiotics for treating ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) increases worldwide. There is a paradox, however, between the large body of experimental evidence supporting the administration of nebulized rather than intravenous aminoglycosides and colistin to treat inoculation pneumonia caused by GNB [1, 2], and the paucity of clinical studies confirming such a benefit in VAP. Based on the recommendations of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) [3, 4], the present article examines this apparent contradiction and suggests some directions for further research and clinical practice.
Original languageEnglish
JournalIntensive care medicine
Early online date8 Jan 2020
DOIs
Publication statusPublished - 2020

Fingerprint

Dive into the research topics of 'Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin'. Together they form a unique fingerprint.

Cite this